항진균제 시장 보고서 : 약물 종류별, 적응증별, 지역별(2026-2034년)

The global antifungal drugs market size reached USD 16.0 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 20.9 Billion by 2034, exhibiting a growth rate (CAGR) of 2.87% during 2026-2034.The rising prevalence of fungal infections, ongoing advancement in antifungal drug development, improved diagnostic technologies, and expanding geriatric population, are primarily driving the market's growth.

Antifungal Drugs Market Trends:

Rising Prevalence of Fungal Infections

The frequency of fungal infections, such as candidiasis, aspergillosis, and dermatophyte infections, is on the rise. For instance, according to an article published by Global Action for Fungal Infections, each year, more than 80 million individuals are at high risk of dying from a fungal disease or losing their vision. Every year, approximately 6 million patients contract life-threatening fungal infections, with nearly 3.75 million dying as a result. This increase in cases drives higher demand for antifungal treatments to manage and treat these infections effectively.

Emergence of Chronic Diseases

The increasing number of individuals with chronic conditions, such as diabetes and cancer, heightens the risk of fungal infections. For instance, according to the World Health Organization (WHO), in 2022, there were nearly 20 million new cancer diagnoses and 9.7 million fatalities. About 1 in 5 people develop cancer in their lifetime, and about 1 in 9 men and 1 in 12 women die from it. Similarly, according to an article published by the American Cancer Society, in 2024, nearly 2,001,000 new cancer cases and approximately 611,700 cancer deaths were expected in the United States. Patients undergoing cancer treatments or those with chronic illnesses often have weakened immune systems, making them more susceptible to infections. These factors further positively influence the antifungal drugs market forecast.

Technological Advancements

Advances in diagnostic tools, such as rapid molecular tests and improved imaging techniques, enable earlier and more accurate diagnosis of fungal infections. This leads to increased use of antifungal treatments. For instance, in February 2024, HaystackAnalytics, based at IIT-Bombay, and NIMS Medicity, located in Neyyattinkara, collaborated to introduce 'infexnTM', a genomics test for identifying infectious disorders. The 'infexnTM' is a cutting-edge targeted next-generation sequencing test designed to detect any fungal infection, thereby boosting the antifungal drugs market revenue.

Global Antifungal Drugs Industry Segmentation:

The publisher provides an analysis of the key trends in each segment of the global antifungal drugs market report, along with forecasts at the global, regional, and country levels from 2026-2034. Our report has categorized the market based on drug class and indication.

Breakup by Drug Class:

• Azoles
• Voriconazole (Vfend)
• Posaconazole (Noxafil)
• Clotrimazole (Canesten)
• Isavuconazole (CRESEMBA)
• Others
• Echinocandins
• Caspofungin (Cancidas)
• Micafungin (Mycamine/ Funguard)
• Others
• Polyenes
• Amphotericin (AmBisome)
• Others
• Allylamines
• Terbinafine (Lamisil)
• Others
• Others

Azoles currently hold the largest market share

According to the antifungal drugs market outlook, azoles are effective against a broad spectrum of fungi, including Candida species, Aspergillus species, and dermatophytes. This broad activity makes them suitable for treating a wide range of fungal infections. Moreover, the emergence of drug-resistant fungal strains, such as resistant Candida and Aspergillus species, has created a need for effective antifungal treatments. New azoles and those with improved pharmacological profiles are being developed to address these resistance issues. Azoles are often used in combination with other antifungal agents to enhance efficacy against resistant strains and reduce the risk of resistance development.

Breakup by Indication:

• Dermatophytosis
• Aspergillosis
• Candidiasis
• Invasive Candidiasis
• Vulvovaginal Candidiasis (VVC)
• Mouth/Throat/Esophageal Candidiasis
• Others
• Others

Currently, candidiasis exhibits a clear dominance in the market

According to the antifungal drugs market overview, candidiasis is one of the most common fungal infections, particularly in immunocompromised patients, including those with HIV/AIDS, cancer, diabetes, or undergoing organ transplants. The high prevalence of this infection drives demand for effective antifungal treatments. Moreover, candidiasis is also a common healthcare-associated infection, particularly in hospitalized patients with central venous catheters or those undergoing invasive procedures. This drives the need for potent antifungal therapies in hospital settings.

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

North America currently dominates the global market

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America currently dominates the global market.

According to the antifungal drugs market statistics, the incidence of fungal infections such as candidiasis, aspergillosis, and cryptococcosis is increasing, partly due to the growing number of immunocompromised patients. For instance, according to an article published by the U.S. Centers for Disease Control and Prevention, an estimated 25,000 cases of candidemia occur in the United States each year. This rise in infection rates drives demand for effective antifungal treatments. Moreover, the incidence of fungal infections such as candidiasis, aspergillosis, and cryptococcosis is increasing, partly due to the growing number of immunocompromised patients. This rise in infection rates drives demand for effective antifungal treatments. Furthermore, innovations in antifungal drug development, including the introduction of new classes of antifungals such as newer azoles and echinocandins, enhance treatment options and drive market growth.

Competitive Landscape:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:

• Abbott Laboratories
• Arcadia Consumer Healthcare Inc.
• Astellas Pharma Inc.
• Bayer AG
• GlaxoSmithKline Plc
• Merck & Co. Inc.
• Merck KGaA
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Scynexis Inc.

Key Questions Answered in This Report

• 1.What was the size of the global antifungal drugs market in 2025?
• 2.What is the expected growth rate of the global antifungal drugs market during 2026-2034?
• 3.What has been the impact of COVID-19 on the global antifungal drugs market?
• 4.What are the key factors driving the global antifungal drugs market?
• 5.What is the breakup of the global antifungal drugs market based on the drug class?
• 6.What is the breakup of the global antifungal drugs market based on the indication?
• 7.What are the key regions in the global antifungal drugs market?
• 8.Who are the key players/companies in the global antifungal drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Antifungal Drugs Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Drug Class

• 6.1 Azoles
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 Voriconazole (Vfend)
    • 6.1.2.2 Posaconazole (Noxafil)
    • 6.1.2.3 Clotrimazole (Canesten)
    • 6.1.2.4 Isavuconazole (CRESEMBA)
    • 6.1.2.5 Others
  • 6.1.3 Market Forecast
• 6.2 Echinocandins
  • 6.2.1 Market Trends
  • 6.2.2 Key Segments
    • 6.2.2.1 Caspofungin (Cancidas)
    • 6.2.2.2 Micafungin (Mycamine/ Funguard)
    • 6.2.2.3 Others
  • 6.2.3 Market Forecast
• 6.3 Polyenes
  • 6.3.1 Market Trends
  • 6.3.2 Key Segments
    • 6.3.2.1 Amphotericin (AmBisome)
    • 6.3.2.2 Others
  • 6.3.3 Market Forecast
• 6.4 Allylamines
  • 6.4.1 Market Trends
  • 6.4.2 Key Segments
    • 6.4.2.1 Terbinafine (Lamisil)
    • 6.4.2.2 Others
  • 6.4.3 Market Forecast
• 6.5 Others
  • 6.5.1 Market Trends
  • 6.5.2 Market Forecast

7 Market Breakup by Indication

• 7.1 Dermatophytosis
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Aspergillosis
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Candidiasis
  • 7.3.1 Market Trends
  • 7.3.2 Key Segments
    • 7.3.2.1 Invasive Candidiasis
    • 7.3.2.2 Vulvovaginal Candidiasis (VVC)
    • 7.3.2.3 Mouth/Throat/Esophageal Candidiasis
    • 7.3.2.4 Others
  • 7.3.3 Market Forecast
• 7.4 Others
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by Region

• 8.1 North America
  • 8.1.1 United States
    • 8.1.1.1 Market Trends
    • 8.1.1.2 Market Forecast
  • 8.1.2 Canada
    • 8.1.2.1 Market Trends
    • 8.1.2.2 Market Forecast
• 8.2 Asia-Pacific
  • 8.2.1 China
    • 8.2.1.1 Market Trends
    • 8.2.1.2 Market Forecast
  • 8.2.2 Japan
    • 8.2.2.1 Market Trends
    • 8.2.2.2 Market Forecast
  • 8.2.3 India
    • 8.2.3.1 Market Trends
    • 8.2.3.2 Market Forecast
  • 8.2.4 South Korea
    • 8.2.4.1 Market Trends
    • 8.2.4.2 Market Forecast
  • 8.2.5 Australia
    • 8.2.5.1 Market Trends
    • 8.2.5.2 Market Forecast
  • 8.2.6 Indonesia
    • 8.2.6.1 Market Trends
    • 8.2.6.2 Market Forecast
  • 8.2.7 Others
    • 8.2.7.1 Market Trends
    • 8.2.7.2 Market Forecast
• 8.3 Europe
  • 8.3.1 Germany
    • 8.3.1.1 Market Trends
    • 8.3.1.2 Market Forecast
  • 8.3.2 France
    • 8.3.2.1 Market Trends
    • 8.3.2.2 Market Forecast
  • 8.3.3 United Kingdom
    • 8.3.3.1 Market Trends
    • 8.3.3.2 Market Forecast
  • 8.3.4 Italy
    • 8.3.4.1 Market Trends
    • 8.3.4.2 Market Forecast
  • 8.3.5 Spain
    • 8.3.5.1 Market Trends
    • 8.3.5.2 Market Forecast
  • 8.3.6 Russia
    • 8.3.6.1 Market Trends
    • 8.3.6.2 Market Forecast
  • 8.3.7 Others
    • 8.3.7.1 Market Trends
    • 8.3.7.2 Market Forecast
• 8.4 Latin America
  • 8.4.1 Brazil
    • 8.4.1.1 Market Trends
    • 8.4.1.2 Market Forecast
  • 8.4.2 Mexico
    • 8.4.2.1 Market Trends
    • 8.4.2.2 Market Forecast
  • 8.4.3 Others
    • 8.4.3.1 Market Trends
    • 8.4.3.2 Market Forecast
• 8.5 Middle East and Africa
  • 8.5.1 Market Trends
  • 8.5.2 Market Breakup by Country
  • 8.5.3 Market Forecast

9 SWOT Analysis

• 9.1 Overview
• 9.2 Strengths
• 9.3 Weaknesses
• 9.4 Opportunities
• 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

• 11.1 Overview
• 11.2 Bargaining Power of Buyers
• 11.3 Bargaining Power of Suppliers
• 11.4 Degree of Competition
• 11.5 Threat of New Entrants
• 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

• 13.1 Market Structure
• 13.2 Key Players
• 13.3 Profiles of Key Players
  • 13.3.1 Abbott Laboratories
    • 13.3.1.1 Company Overview
    • 13.3.1.2 Product Portfolio
    • 13.3.1.3 Financials
    • 13.3.1.4 SWOT Analysis
  • 13.3.2 Arcadia Consumer Healthcare Inc.
    • 13.3.2.1 Company Overview
    • 13.3.2.2 Product Portfolio
  • 13.3.3 Astellas Pharma Inc.
    • 13.3.3.1 Company Overview
    • 13.3.3.2 Product Portfolio
    • 13.3.3.3 Financials
    • 13.3.3.4 SWOT Analysis
  • 13.3.4 Bayer AG
    • 13.3.4.1 Company Overview
    • 13.3.4.2 Product Portfolio
    • 13.3.4.3 Financials
    • 13.3.4.4 SWOT Analysis
  • 13.3.5 GlaxoSmithKline Plc
    • 13.3.5.1 Company Overview
    • 13.3.5.2 Product Portfolio
    • 13.3.5.3 Financials
  • 13.3.6 Merck & Co. Inc.
    • 13.3.6.1 Company Overview
    • 13.3.6.2 Product Portfolio
    • 13.3.6.3 Financials
    • 13.3.6.4 SWOT Analysis
  • 13.3.7 Merck KGaA
    • 13.3.7.1 Company Overview
    • 13.3.7.2 Product Portfolio
    • 13.3.7.3 Financials
    • 13.3.7.4 SWOT Analysis
  • 13.3.8 Novartis AG
    • 13.3.8.1 Company Overview
    • 13.3.8.2 Product Portfolio
    • 13.3.8.3 Financials
    • 13.3.8.4 SWOT Analysis
  • 13.3.9 Pfizer Inc.
    • 13.3.9.1 Company Overview
    • 13.3.9.2 Product Portfolio
    • 13.3.9.3 Financials
    • 13.3.9.4 SWOT Analysis
  • 13.3.10 Sanofi S.A.
    • 13.3.10.1 Company Overview
    • 13.3.10.2 Product Portfolio
    • 13.3.10.3 Financials
    • 13.3.10.4 SWOT Analysis
  • 13.3.11 Scynexis Inc.
    • 13.3.11.1 Company Overview
    • 13.3.11.2 Product Portfolio
    • 13.3.11.3 Financials